Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Multiple Sclerosis Drugs - Chile

Chile
  • The revenue in the Multiple Sclerosis Drugs market in Chile is estimated to reach US$46.34m in 2024.
  • It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.01%, leading to a market volume of US$48.74m by 2029.
  • When compared globally, United States is projected to generate the highest revenue, with US$11.77bn in 2024.
  • The market for multiple sclerosis drugs in Chile is witnessing a surge in demand due to increasing awareness and access to advanced treatment options.

Definition:
This market covers drugs to treat the neurological autoimmune disease multiple sclerosis. As there is no cure for multiple sclerosis, the goal is to improve functions after an attack or to prevent attacks. Different types of medication include immunomodulators, immunosuppressants, and interferons. Monoclonal antibodies are now being increasingly used.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Biogen, Roche, Novartis, Sanofi

In-Scope

  • Drugs to treat multiple sclerosis
  • Monoclonal antibodies
  • Immunosuppressants

Out-Of-Scope

  • Monoclonal antibodies and immunosuppressants for the treatment of other diseases
  • Treatment of other autoimmune diseases
  • Alternative medicine
Multiple Sclerosis Drugs: market data & analysis - Cover

Market Insights report

Multiple Sclerosis Drugs: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    The market for Multiple Sclerosis Drugs in Chile is showing a positive trend in recent years.

    Customer preferences:
    The customer preferences in Chile are shifting towards new and innovative drugs that are more effective in treating Multiple Sclerosis. Patients are willing to pay a premium for drugs that offer better results and have fewer side effects. The demand for oral drugs is also increasing as they are more convenient to use and have a better safety profile.

    Trends in the market:
    The market for Multiple Sclerosis Drugs in Chile is growing at a steady pace due to the increasing prevalence of the disease. The availability of new drugs and therapies is also contributing to the growth of the market. The market is dominated by a few multinational pharmaceutical companies that have a strong presence in the country. These companies are investing heavily in research and development to bring new and innovative drugs to the market.

    Local special circumstances:
    Chile has a well-developed healthcare system that provides access to quality healthcare to its citizens. The government is also taking steps to improve the accessibility and affordability of healthcare services. The country has a large aging population, which is more susceptible to Multiple Sclerosis. The increasing awareness about the disease and its treatment options is also contributing to the growth of the market.

    Underlying macroeconomic factors:
    Chile has a stable economy with a strong focus on exports. The country has a favorable business environment and a well-developed infrastructure. The government is also taking steps to attract foreign investment in the healthcare sector. The pharmaceutical industry in Chile is highly regulated, and the government has implemented strict pricing policies to ensure that drugs are affordable for all. The increasing demand for healthcare services in the country is also contributing to the growth of the market for Multiple Sclerosis Drugs.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Multiple Sclerosis Drugs: market data & analysis - BackgroundMultiple Sclerosis Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.